In obese Blacks presenting with diabetic ketoacidosis (DKA) at new-onset of diabetes, intensive insulin treatment improves β-cell function so that ˜70% achieve near-normoglycemia remission (HbA1c < 7%, fasting blood glucose [BG]<130 mg/dl while off insulin for ≥1 week) and maintain glycemic control without medications. The 2021 American Diabetes Association (ADA) consensus defined diabetes remission as HbA1c <6.5% or BG 126 mg/dl while off medications for >3 months. It is unknown whether glycemic measures and insulin secretion differ between patients who achieve the new ADA definition of remission (intensive remission [IR]) compared to near-normoglycemia remission (non-intensive remission [NIR]) .We performed 75-g, 240-minute (min) oral glucose tolerance tests (OGTT) in 13 obese (BMI>30 kg/m2) Blacks who presented with DKA (BG>250 mg/dl, HCO3<18 mEq/L, pH<7.3) and achieved remission from insulin. Glucose and C-peptide levels were measured at -15, 0, 10, 20, 30, 60, 90, 120, 180 and 240 min during OGTT. Insulin secretory rates (ISR) , first phase (Φdynamic) , second phase (Φstatic) and total (Φtotal) insulin secretion were calculated using a previously published model. Data was compared between IR, (HbA1c<6.5%, n=7) vs. NIR, (HbA1c≥6.5%, n=6)) There were no differences in age, BMI and mean BG levels during OGTT between groups. Model estimates of Φdynamic were significant (P=0.046) and 5-fold higher in IR (Marginal Mean: 514.00, 95% CI: 134.53-893.47 [109]) vs. NIR (Marginal Mean: 100, 95% CI: 100.45, 95% CI: -41.97-242.87 [109]) . Estimates of Φstatic were significant (P=0.022) and 2-fold higher in the IR (Marginal Mean: 31.84, 95% CI: 19.88-43.80 [min-1]) vs. NIR (Marginal Mean: 14.59, 95% CI: 6.79-22.39 [min-1]) with no significant (P=0.058) group differences between Φtotal.In comparison to NIR, obese Blacks with IR exhibit marked preservation of β-cell function suggesting that HbA1c <6.5% should be targeted for insulin remission after presentation with DKA.


D.Stefanovski: None. O.Oladejo: None. G.E.Umpierrez: Research Support; AstraZeneca, Dexcom, Inc., Novo Nordisk. P.Vellanki: n/a.


NIH/NIDDK K23 DK11324-01A1

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at